Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05033964
Registration number
NCT05033964
Ethics application status
Date submitted
17/08/2021
Date registered
5/09/2021
Date last updated
18/04/2023
Titles & IDs
Public title
The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
Query!
Scientific title
The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
Query!
Secondary ID [1]
0
0
ELX-CL-2005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary Artery Disease
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Combination Product - Percutaneous Coronary Intervention with drug eluting stents
Experimental: DESyne BDS Plus Arm - DESyne BDS Plus Drug Eluting Coronary Stent System (DESyne BDS Plus DECSS; DESyne BDS Plus) is loaded with Sirolimus, Rivaroxaban and Argatroban
Active Comparator: DESyne X2 Arm - The DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2 NECSS; DESyne X2) is loaded with Novolimus
Combination Product: Percutaneous Coronary Intervention with drug eluting stents
Coronary drug eluting stent implantation
Query!
Intervention code [1]
0
0
Combination Product
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Target lesion failure
Query!
Assessment method [1]
0
0
defined as a per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target lesion revascularization
Query!
Timepoint [1]
0
0
3 days or through hospital discharge, whichever comes first
Query!
Secondary outcome [1]
0
0
Acute success
Query!
Assessment method [1]
0
0
defined as the successful delivery of the designated device and a final residual stenosis < 30% by QCA without TLF
Query!
Timepoint [1]
0
0
during hospital stay with a maximum of first seven days post index procedure
Query!
Secondary outcome [2]
0
0
Target lesion failure
Query!
Assessment method [2]
0
0
defined as a per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target lesion revascularization
Query!
Timepoint [2]
0
0
30 days
Query!
Secondary outcome [3]
0
0
Target lesion failure
Query!
Assessment method [3]
0
0
defined as a per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target lesion revascularization
Query!
Timepoint [3]
0
0
6 months
Query!
Secondary outcome [4]
0
0
Target lesion failure
Query!
Assessment method [4]
0
0
defined as a per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target lesion revascularization
Query!
Timepoint [4]
0
0
12 months
Query!
Secondary outcome [5]
0
0
Target lesion failure
Query!
Assessment method [5]
0
0
defined as a per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target lesion revascularization
Query!
Timepoint [5]
0
0
2 years
Query!
Secondary outcome [6]
0
0
Target lesion failure
Query!
Assessment method [6]
0
0
defined as a per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target lesion revascularization
Query!
Timepoint [6]
0
0
3 years
Query!
Secondary outcome [7]
0
0
Death
Query!
Assessment method [7]
0
0
Cardiovascular and Non-cardiovascular
Query!
Timepoint [7]
0
0
3 days or through hospital discharge, whichever comes first
Query!
Secondary outcome [8]
0
0
Death
Query!
Assessment method [8]
0
0
Cardiovascular and Non-cardiovascular
Query!
Timepoint [8]
0
0
30 days
Query!
Secondary outcome [9]
0
0
Death
Query!
Assessment method [9]
0
0
Cardiovascular and Non-cardiovascular
Query!
Timepoint [9]
0
0
6 months
Query!
Secondary outcome [10]
0
0
Death
Query!
Assessment method [10]
0
0
Cardiovascular and Non-cardiovascular
Query!
Timepoint [10]
0
0
12 months
Query!
Secondary outcome [11]
0
0
Death
Query!
Assessment method [11]
0
0
Cardiovascular and Non-cardiovascular
Query!
Timepoint [11]
0
0
2 years
Query!
Secondary outcome [12]
0
0
Death
Query!
Assessment method [12]
0
0
Cardiovascular and Non-cardiovascular
Query!
Timepoint [12]
0
0
3 years
Query!
Secondary outcome [13]
0
0
Myocardial Infarction
Query!
Assessment method [13]
0
0
Q-wave and non-Q-wave; Target vessel and non-target vessel
Query!
Timepoint [13]
0
0
3 days or through hospital discharge, whichever comes first
Query!
Secondary outcome [14]
0
0
Myocardial Infarction
Query!
Assessment method [14]
0
0
Q-wave and non-Q-wave; Target vessel and non-target vessel
Query!
Timepoint [14]
0
0
30 days
Query!
Secondary outcome [15]
0
0
Myocardial Infarction
Query!
Assessment method [15]
0
0
Q-wave and non-Q-wave; Target vessel and non-target vessel
Query!
Timepoint [15]
0
0
6 months
Query!
Secondary outcome [16]
0
0
Myocardial Infarction
Query!
Assessment method [16]
0
0
Q-wave and non-Q-wave; Target vessel and non-target vessel
Query!
Timepoint [16]
0
0
12 months
Query!
Secondary outcome [17]
0
0
Myocardial Infarction
Query!
Assessment method [17]
0
0
Q-wave and non-Q-wave; Target vessel and non-target vessel
Query!
Timepoint [17]
0
0
2 years
Query!
Secondary outcome [18]
0
0
Myocardial Infarction
Query!
Assessment method [18]
0
0
Q-wave and non-Q-wave; Target vessel and non-target vessel
Query!
Timepoint [18]
0
0
3 years
Query!
Secondary outcome [19]
0
0
Target Lesion Revascularization
Query!
Assessment method [19]
0
0
Clinically indicated and non-clinically indicated
Query!
Timepoint [19]
0
0
3 days or through hospital discharge, whichever comes first
Query!
Secondary outcome [20]
0
0
Target Lesion Revascularization
Query!
Assessment method [20]
0
0
Clinically indicated and non-clinically indicated
Query!
Timepoint [20]
0
0
30 days
Query!
Secondary outcome [21]
0
0
Target Lesion Revascularization
Query!
Assessment method [21]
0
0
Clinically indicated and non-clinically indicated
Query!
Timepoint [21]
0
0
6 months
Query!
Secondary outcome [22]
0
0
Target Lesion Revascularization
Query!
Assessment method [22]
0
0
Clinically indicated and non-clinically indicated
Query!
Timepoint [22]
0
0
12 months
Query!
Secondary outcome [23]
0
0
Target Lesion Revascularization
Query!
Assessment method [23]
0
0
Clinically indicated and non-clinically indicated
Query!
Timepoint [23]
0
0
2 Years
Query!
Secondary outcome [24]
0
0
Target Lesion Revascularization
Query!
Assessment method [24]
0
0
Clinically indicated and non-clinically indicated
Query!
Timepoint [24]
0
0
3 Years
Query!
Secondary outcome [25]
0
0
Target Vessel Failure
Query!
Assessment method [25]
0
0
per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target vessel revascularization
Query!
Timepoint [25]
0
0
3 days or through hospital discharge, whichever comes first
Query!
Secondary outcome [26]
0
0
Target Vessel Failure
Query!
Assessment method [26]
0
0
per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target vessel revascularization
Query!
Timepoint [26]
0
0
30 days
Query!
Secondary outcome [27]
0
0
Target Vessel Failure
Query!
Assessment method [27]
0
0
per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target vessel revascularization
Query!
Timepoint [27]
0
0
6 months
Query!
Secondary outcome [28]
0
0
Target Vessel Failure
Query!
Assessment method [28]
0
0
per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target vessel revascularization
Query!
Timepoint [28]
0
0
12 months
Query!
Secondary outcome [29]
0
0
Target Vessel Failure
Query!
Assessment method [29]
0
0
per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target vessel revascularization
Query!
Timepoint [29]
0
0
2 years
Query!
Secondary outcome [30]
0
0
Target Vessel Failure
Query!
Assessment method [30]
0
0
per-subject composite endpoint of cardiovascular death, target vessel MI, and clinically-indicated target vessel revascularization
Query!
Timepoint [30]
0
0
3 years
Query!
Secondary outcome [31]
0
0
Late Lumen Loss
Query!
Assessment method [31]
0
0
powered secondary endpoint assessed by QCA in a subset of patients
Query!
Timepoint [31]
0
0
6 months
Query!
Secondary outcome [32]
0
0
Optical Coherence Tomography (OCT) imaging
Query!
Assessment method [32]
0
0
assessment of the lesion and stent in a subset of patients.
Query!
Timepoint [32]
0
0
Post procedure and 6 months
Query!
Secondary outcome [33]
0
0
Pharmacokinetic profile of the drugs on the DESyne BDS Plus Stent
Query!
Assessment method [33]
0
0
assessment of the blood pharmacokinetics of the three drugs eluted from the DESyne BDS Plus after implantation
Query!
Timepoint [33]
0
0
pre-treatment, and post-treatment at 10 minutes, 30 minutes, 1, 2, 4, 6, 12, 24, 72 hours, and 7 days
Query!
Eligibility
Key inclusion criteria
1. Patient must be at least 18 years of age
2. Patient is able to understand the risks, benefits and treatment alternatives of
receiving the DESyne BDS Plus DECSS or the DESyne X2 NECSS and provide written
informed consent or oral consent (in urgent PCI) as allowed per hospital standard and
as approved by the local Ethics Committee, prior to any clinical study-related
procedure
3. Indication for a percutaneous intervention with stent implantation in native
epicardial arteries including patients with stable coronary artery disease and acute
coronary syndromes including NSTEMI and STEMI.
4. Patient must be an acceptable candidate for coronary artery bypass graft (CABG)
surgery
5. Patient agrees to undergo all clinical study required follow up visits, angiograms,
and imaging testing (as applicable)
6. Patient agrees not to participate in any other clinical research study for a period of
one year following the index procedure (long term follow-up or observational studies
are permitted)
Angiographic Inclusion Criteria
7. Target lesion(s) must be de novo coronary artery lesion(s) and must be located in a
separate* vessel from other target or non-target lesions.
8. Target lesion(s) must have a reference vessel diameter (RVD) of = 2.25 and = 3.5 mm by
visual estimation
9. Target lesion(s) must measure = 34 mm in length, and able to be covered by a single
device with 2 mm of healthy vessel on either side of planned implantation site
10. Target lesion(s) must be in a major artery or branch with a visually estimated
stenosis of = 50% and <100%. When two target lesions are treated, they must be located
in separate major epicardial vessels
Additional Inclusion Criteria for PK study:
11. Patients participating in PK study must meet all general and angiographic
inclusion/exclusion criteria and may be treated with only the DESyne BDS Plus during
Index Procedure.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Acute myocardial infarction with Killip Class III and IV
2. Acute myocardial infarction requiring resuscitation
3. Acute myocardial infarction requiring IABP or ventilation support
4. Patient had fibrinolysis prior to PCI
5. Patient has current unstable ventricular arrhythmias
6. Patient has a known left ventricular ejection fraction (LVEF) < 30%
7. Patient has received a heart transplant or any other organ transplant or is on a
waiting list for an organ transplant
8. Patient is receiving or scheduled to receive chemotherapy for malignancy within 30
days prior to or after the procedure
9. Patient is receiving immunosuppression therapy, other than steroids or has known
immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic
lupus erythematosus, etc.)
10. Patient has a known hypersensitivity or contraindication to aspirin, both heparin and
bivalirudin, clopidogrel, prasugrel or ticagrelor, Novolimus, Sirolimus, Rivaroxaban,
Argatroban, CoCr alloys, PLLA polymers or contrast sensitivity that cannot be
adequately pre-medicated
11. Elective surgery is planned within the first 6 months after the procedure that will
require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors
12. Patient has severe renal dysfunction (CKD IV or V, eGFR <30) or is on dialysis
13. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological
attack (TIA) within the past six months
14. Patient has had a significant GI or urinary bleed within the past six months
15. Women of childbearing potential (unless they have a negative pregnancy test within 7
days of index procedure), or women who are pregnant or nursing
16. Patient has other medical conditions or known history of substance abuse (alcohol,
cocaine, heroin, etc.) that may cause non-compliance with the clinical study plan,
confound the data interpretation, or be associated with a limited life expectancy
(i.e., less than one year)
17. Patient is already participating in another clinical study which has not reached the
primary endpoint (long-term follow-up or observational studies are permitted)
Angiographic Exclusion Criteria
18. Patient with vessel rupture and/or visible pericardial effusion
19. Target lesion aorto-ostial location or within 5mm of the origin of the vessel (LAD,
LCX, RCA)
20. Target lesion is severely calcified and/or requires use of rotational atherectomy or
cutting balloon, the use of shockwave or scoring balloon is allowed
21. Target Lesion located in the Left Main artery
22. Target Lesion located within an arterial or saphenous vein graft or distal to a
diseased arterial or saphenous vein graft
23. Target Lesion involves a bifurcation >2.5 mm, or which requires a planned 2 or more
stent technique
24. Previous placement of a stent within 10 mm of a target lesion
25. Another clinically-significant lesion (> 50%) is located in the same major epicardial
vessel as a target lesion
26. Target vessel was previously treated with any type of PCI < 6 months prior to index
procedure
27. Unsuccessful or complicated PCI in a non-target vessel < 48 hours prior to index
procedure
28. Target vessel has a planned staged PCI = 6 months after the index procedure
Additional Exclusion Criteria for PK study:
29. Target vessel was previously treated with any type of PCI < 6 months prior to index
procedure
30. Patient with planned staged PCI within 90 days after study procedure
31. Patients who have a non-target lesion treated during the study procedure
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
15/12/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/03/2026
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Antwerp
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Brugge
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Genk
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Leuven
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
São Paulo
Query!
Country [6]
0
0
Czechia
Query!
State/province [6]
0
0
Prague
Query!
Country [7]
0
0
Netherlands
Query!
State/province [7]
0
0
Eindhoven
Query!
Country [8]
0
0
New Zealand
Query!
State/province [8]
0
0
Auckland
Query!
Country [9]
0
0
New Zealand
Query!
State/province [9]
0
0
Christchurch
Query!
Country [10]
0
0
New Zealand
Query!
State/province [10]
0
0
Dunedin
Query!
Country [11]
0
0
New Zealand
Query!
State/province [11]
0
0
Hamilton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Elixir Medical Corporation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The objective of this clinical trial is to confirm the safety, effectiveness and performance
of the DESyne BDS Plus Drug Eluting Coronary Stent System (DESyne BDS Plus DECSS) (Test) as
compared to the CE Mark approved DESyne X2 Novolimus Eluting Coronary Stent System (DESyne X2
NECSS; DESyne X2) (Control) in the treatment of de novo native coronary artery lesions.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05033964
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Stefan Verheye, MD, PHD
Query!
Address
0
0
Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim, Antwerp, Belgium
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05033964
Download to PDF